公开(公告)号：US10030071B2

公开(公告)日：2018-07-24

申请号：US14916943

申请日：2014-09-05

申请人： UNIVERSITY OF MIYAZAKI ,  FUJITA HEALTH UNIVERSITY ,  PERSEUS PROTEOMICS INC.

发明人： Kazuhiro Morishita ,  Kazuko Kaneda ,  Yoshikazu Kurosawa ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Katsushi Kouda ,  Yoshinori Ukai

IPC分类号： A61K39/395 ,  C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  A61K31/365 ,  A61K31/704 ,  A61K31/7068 ,  A61K39/00

摘要： It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.

公开(公告)号：US09593165B2

公开(公告)日：2017-03-14

申请号：US14441307

申请日：2013-11-08

申请人： UNIVERSITY OF MIYAZAKI ,  PERSEUS PROTEOMICS INC.

发明人： Yoshikazu Kurosawa ,  Kazuhiro Morishita ,  Lilin Zhang ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Yukio Sudo ,  Fumiko Nomura ,  Yoshinori Ukai

IPC分类号： C12P21/04 ,  C12P21/06 ,  C12N5/00 ,  C07H21/04 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC分类号： C07K16/2881 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92

摘要： The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.

摘要翻译： 本发明提供一种抗体，其中重链第一互补决定区（VH CDR1），重链第二互补决定区（VH CDR2）和重链第三互补决定区（VH CDR3）示于SEQ ID NOS：1,2和7，分别示出轻链第一互补决定区（VL CDR1），轻链第二互补决定区（VL CDR2）和轻链第三互补决定区（VL CDR3） 分别为SEQ ID NO：4,5和6。

公开(公告)号：US20150291697A1

公开(公告)日：2015-10-15

申请号：US14441307

申请日：2013-11-08

申请人： UNIVERSITY OF MIYAZAKI ,  PERSEUS PROTEOMICS INC.

发明人： Yoshikazu Kurosawa ,  Kazuhiro Morishita ,  Lilin Zhang ,  Gene Kurosawa ,  Katsuyuki Mitomo ,  Yukio Sudo ,  Fumiko Nomura ,  Yoshinori Ukai

IPC分类号： C07K16/28

CPC分类号： C07K16/2881 ,  A61K2039/505 ,  C07K16/30 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92

摘要： The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.

摘要翻译： 本发明提供一种抗体，其中重链第一互补决定区（VH CDR1），重链第二互补决定区（VH CDR2）和重链第三互补决定区（VH CDR3）示于SEQ ID NOS：1,2和7，分别示出轻链第一互补决定区（VL CDR1），轻链第二互补决定区（VL CDR2）和轻链第三互补决定区（VL CDR3） 分别为SEQ ID NO：4,5和6。

公开(公告)号：US09644028B2

公开(公告)日：2017-05-09

申请号：US14768151

申请日：2014-02-14

申请人： PERSEUS PROTEOMICS INC.

发明人： Keisuke Ishii ,  Katsuyuki Mitomo ,  Katsushi Kouda ,  Fumiko Nomura ,  Yoko Kayukawa ,  Tadashi Matsuura

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K47/48

CPC分类号： C07K16/28 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565

摘要： The present invention provides an anti-CDH3 humanized antibody having lower immunogenicity, and an anti-CDH3 humanized antibody drug conjugate having the aforementioned anti-CDH3 humanized antibody. The present invention provides a conjugate of an anti-CDH3 humanized antibody and a drug by conjugating a drug having cytotoxicity to an anti-CDH3 humanized antibody having complementarity determining region sequences derived from the heavy chain variable region of an antibody produced by cells having Accession No. NITE BP-1536, and complementarity determining region sequences derived from the light chain variable region thereof, and which also comprises a heavy chain human subgroup III consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the heavy chain variable region, and a light chain human κ subgroup I consensus framework sequence or a human germline sequence selected under optimal alignment as a framework region sequence of the light chain variable region.